3rd ESTRO Forum 2015 S659 regression analysis showed an interesting, but not statistically significant trend: better pathological responses were seen in patients presenting more important reduction of SUV max and SUV mean (Fig. 1) .
Purpose/Objective: To report the 4-year outcomes of a consecutive prospective series of anal cancer patients treated with concurrent chemo-radiation delivered with intensity-modulated radiotherapy (IM-RT), employing a simultaneous integrated boost (SIB) approach. Materials and Methods: A prospective series of 54 patients was enrolled between 2007 and 2013. Treatment schedule consisted of 50.4 Gy/28 fractions (1.8 Gy daily) to the gross tumor volume, while the elective nodal volumes were prescribed 42 Gy/28 fractions (1.5 Gy/daily) for patients having a cT2N0 disease. Patients with cT3-T4/N0-N3 tumors were prescribed 54 (T3) or 59.4 (T4) Gy/30 fractions (1.8 Gy daily) to the gross tumor volume; gross nodal volumes were prescribed 50.4 Gy/30 fr (1.68 Gy daily) if sized < 3 cm or 54 Gy/30 fr (1.8 Gy daily) if > 3 cm; elective nodal regions were given 45 Gy/30 fractions (1.5 Gy daily). Chemotherapy was administred concurrently according to the Nigro's regimen. Primary endpoints was colostomy-free survival (CFS). Secondary end-points were local control (LC), disease-free survival (DFS), cancer-specific survival (CSS), overall survival (OS) and toxicity profile. Results: Median follow up was 32.6 months (range 12-84). The actuarial probability of being alive at 4 years without a colostomy (CFS) was 68.9 % (95% CI: 50.3-84.7%). Actuarial 4year OS, CSS, DFS and LC were 77.7% (95% CI: 60.7-88.1%), 81.5% (95% CI: 64-91%), 65.5% (95% CI: 47.7-78.5%) and 84.6% (95% CI: 71.6-92%). Actuarial 4-year metastasis-free survival was 74.4% (95% CI: 55.5-86.2%). Maximum detected acute toxicities were as follows: dermatologic -G3: 13%; GI-G3: 8%; GU-G3: 2%; anemia-G3: 2%; neutropenia-G3:11%; G4: 2%; thrombocytopenia-G3:2%. Four-year G2 chronic toxicity rates were 2.5% (95% CI: 3.6-16.4) for GU, 14.4% (95% CI: 7.1-28) for GI, 3.9% (95% CI: 1-14.5%) for skin and 4.2% (95% CI: 1.1-15.9) for genitalia. Conclusions: Our findings support the feasibility of IMRT in the combined modality treatment of anal cancer, with comparable results to the literature with respect to local control, spinchter preservation and survival. Acute toxicity is lower if compared to series employing standard techniques. Our results support the use of IMRT on a routine basis for the treatment of anal cancer. 
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